An open-label, randomized, crossover, comparative bioavailability study of Levodopa Cyclops ® and Inbrija® in healthy adult subjects

Background: Many Parkinson ’s disease (PD) patients experience OFF episodes when their disease progresses. OFF episodes are very debilitating and require medication with a predictable and fast onset of effect. This unmet medical need was addressed by apomorphine-based products and Inbrija®, but these products still have li mitations for the patient. Levodopa Cyclops® is a pre-filled, ready-to-use, single-use dry powder inhaler that offers PD patients unrivaled ease-of-use. Previous studies in PD patients have shown Levodopa Cyclops®’ rapid onset of action, ease-of-use during OFF episodes, fast efficacy (
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research